CN113631165A - 用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂 - Google Patents

用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂 Download PDF

Info

Publication number
CN113631165A
CN113631165A CN202080023125.XA CN202080023125A CN113631165A CN 113631165 A CN113631165 A CN 113631165A CN 202080023125 A CN202080023125 A CN 202080023125A CN 113631165 A CN113631165 A CN 113631165A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
hydrate
pneumocystis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080023125.XA
Other languages
English (en)
Chinese (zh)
Inventor
D·A·安古洛·冈萨雷斯
S·A·巴拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scynexis Inc
Original Assignee
Scynexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis Inc filed Critical Scynexis Inc
Publication of CN113631165A publication Critical patent/CN113631165A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080023125.XA 2019-02-27 2020-02-25 用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂 Pending CN113631165A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
US62/811,456 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (1)

Publication Number Publication Date
CN113631165A true CN113631165A (zh) 2021-11-09

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080023125.XA Pending CN113631165A (zh) 2019-02-27 2020-02-25 用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂

Country Status (15)

Country Link
US (1) US12594266B2 (https=)
EP (1) EP3930716B1 (https=)
JP (1) JP7581219B2 (https=)
KR (1) KR20210133241A (https=)
CN (1) CN113631165A (https=)
AU (1) AU2020228036B2 (https=)
BR (1) BR112021016876A2 (https=)
CA (1) CA3131298A1 (https=)
EA (1) EA202192344A1 (https=)
ES (1) ES3055272T3 (https=)
IL (1) IL285839A (https=)
MA (1) MA55081A (https=)
MX (2) MX2021010311A (https=)
TW (1) TWI910099B (https=)
WO (1) WO2020176527A1 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
CN101454010A (zh) * 2006-04-03 2009-06-10 默克公司 抗真菌剂
WO2018191077A1 (en) * 2017-04-10 2018-10-18 Scynexis, Inc. Antifungal agents used in combination
US20190000917A1 (en) * 2016-01-08 2019-01-03 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
CN101454010A (zh) * 2006-04-03 2009-06-10 默克公司 抗真菌剂
US20190000917A1 (en) * 2016-01-08 2019-01-03 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
WO2018191077A1 (en) * 2017-04-10 2018-10-18 Scynexis, Inc. Antifungal agents used in combination
WO2019028034A1 (en) * 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: ""SCYNEXIS Data Presentations atECCMID2018 Show SCY-078 Potent and Synergistic Antifungal Activity Against Aspergillus and Pneumocystis"", 《SCYNEXIS ECCMID2018》, pages 1 - 5 *
BORROTO-ESODA K,ET AL.,: "\"SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis\"", 《OPEN FORUM INFECTIOUS DISEASES》, no. 1, pages 1056 - 1059 *
CUSHION M, ET AL.: ""SCY-078 Demonstrates Antifungal Activity Against Pneumocystis in a Prophylactic Murine Model of Pneumocystis Pneumonia"", pages 2, Retrieved from the Internet <URL:https://www.prnewswire.com/news-releases/scynexis-data-presentations-at-eccmid-2018-show-scy-078-potent-and-synergistic-antifungal-activity-against-aspergillus-and-pneumocystis-300633617.html> *

Also Published As

Publication number Publication date
MX2021010311A (es) 2022-01-04
JP2022523212A (ja) 2022-04-21
KR20210133241A (ko) 2021-11-05
WO2020176527A1 (en) 2020-09-03
US12594266B2 (en) 2026-04-07
AU2020228036A1 (en) 2021-09-23
TWI910099B (zh) 2026-01-01
MA55081A (fr) 2022-01-05
JP7581219B2 (ja) 2024-11-12
AU2020228036B2 (en) 2025-08-07
EP3930716B1 (en) 2025-09-10
IL285839A (en) 2021-10-31
EP3930716A1 (en) 2022-01-05
BR112021016876A2 (pt) 2021-11-03
MX2025004197A (es) 2025-09-02
ES3055272T3 (en) 2026-02-10
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
US20230149376A1 (en) 2023-05-18
EA202192344A1 (ru) 2021-11-15

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
CN113631165A (zh) 用于治疗或预防肺囊虫属肺炎的三萜类抗真菌剂
HK40062347A (en) Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia
JP7562542B2 (ja) 真菌性骨－関節感染症を治療するためのトリテルペノイド系抗真菌薬
IL288165B1 (en) Antifungal agents for decolonization of Candida auris
HK40066679A (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40066679B (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062347

Country of ref document: HK